Abiopharma

🔍 BROADWOOD PARTNERS, L.P. (Executive)

Company: Insight Molecular Diagnostics Inc. (IMDX)

Report Date: 2026-04-23

Detailed Transactions and Holdings:

• Acquired 280,381 shares of Common Stock, no par value at $3.5025 per share (Direct)
  Date: 2026-04-23 | Code: P | equity_swap_involved: 0 | shares_owned_after: 12,395,081.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Acquired 0 shares of Common Stock, no par value (Direct)
  Date: 2026-04-23 | Code: P | equity_swap_involved: 0 | shares_owned_after: 12,395,081.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 38,880 shares of Common Stock, no par value at $3.5258 per share (Direct)
  Date: 2026-04-24 | Code: P | equity_swap_involved: 0 | shares_owned_after: 12,433,961.00 | transaction_form_type: 4 | Footnotes: F4, F1
• Acquired 0 shares of Common Stock, no par value (Direct)
  Date: 2026-04-24 | Code: P | equity_swap_involved: 0 | shares_owned_after: 12,433,961.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 250,923 shares of Common Stock, no par value at $3.6391 per share (Direct)
  Date: 2026-04-27 | Code: P | equity_swap_involved: 0 | shares_owned_after: 12,684,884.00 | transaction_form_type: 4 | Footnotes: F5, F1
• Acquired 0 shares of Common Stock, no par value (Direct)
  Date: 2026-04-27 | Code: P | equity_swap_involved: 0 | shares_owned_after: 12,684,884.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock, no par value (Direct)
  Date: 2026-04-23 | Code: H | shares_owned_after: 157.00 | Footnotes: F2
• Holds 150,093 shares of Warrant to Purchase Common Stock at $30.6 per share (Derivative)
  Date: 2026-04-23 | Code: H | Expires: 2027-04-19 | shares_owned_after: 150,093.00 | Footnotes: F6, F1
• Holds 150,093 shares of Warrant to Purchase Common Stock at $30.6 per share (Derivative)
  Date: 2026-04-23 | Code: H | Expires: 2027-04-19 | shares_owned_after: 150,093.00 | Footnotes: F6, F1

Footnotes:

• F1: The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
• F2: These securities are directly owned by Neal C. Bradsher.
• F3: This constitutes the weighted average purchase price. The prices range from $3.39 to $3.54. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the "SEC Staff"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
• F4: This constitutes the weighted average purchase price. The prices range from $3.47 to $3.59. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
• F5: This constitutes the weighted average purchase price. The prices range from $3.50 to $3.84. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
• F6: These warrants are currently exercisable.